Three Samsung biotech companies form business partnership with Moderna parent company in the US = South Korean report

Samsung C&T and its subsidiaries, Samsung Biologics and Samsung Bioepis, are working with a U.S. venture investment company in the "Life Science Fund No. 2" formed by the three companies.
The company announced that it has signed a memorandum of understanding (MOU) with Flagship Pioneering (FP). This will enable the four companies to commercialize artificial intelligence (AI) and basic science research in the biofield.
The two companies will collaborate on research on intermediary functions, cutting-edge technology related to biopharmaceutical development platforms, and high-quality clinical trial infrastructure. In addition, we are promoting interaction with a variety of startups under the FP umbrella.
I'm going to go to the middle of the day. FP, the parent company of the US biopharmaceutical Moderna, has total assets under management of 19 trillion won (approximately 2 trillion yen) since its founding in 2000. So far, we have invested in 165 companies, over 100
has been established. The three companies, including Samsung C&T, will work together with FP to produce Moderna's COVID-19 virus vaccine at Samsung Biologics starting in October 2021.
We continue to cooperate. In August 2022, we will invest $15 million (USD, approximately 2,156.52 million yen) through the "Life Science No. 1 Fund" to Senda Bioscience, a subsidiary of FP.
) invested.